Oncology & Cancer
Cabazitaxel can offer an advantage in certain patients
Cabazitaxel (trade name: Jevtana) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic ...
May 29, 2012
0
0